Wedbush Starts Prime Medicine (PRME) at Outperform

April 2, 2024 4:10 PM EDT Send to a Friend
Wedbush analyst David Nierengarten initiates coverage on Prime Medicine (NASDAQ: PRME) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to Premium below (Free Trial) LEARN MORE

Member Login